

Materials for this course will release 02/02/2022

Intensive Studies for Recertification: Pharmacotherapy (Cert # L229093)

Teaser: The Pharmacotherapy Intensive Studies for Recertification Package consists of 4 activities and provides up to 6.5 contact hours of recertification credit through a high-level, interactive discussion on contemporary and emerging issues in pharmacotherapy.

Tag: Certifications; Pharmacotherapy



ACPE Numbers:

0204-0000-21-315-H02-P
0204-0000-21-246-H01-P
0204-0000-21-269-H01-P
0204-0000-21-305-H01-P

Pre-Sale Date: 01/04/2022

Content Release Date: 02/02/2022

Expiration Date: 01/31/2023

Activity Type: Application-based

CE Credits: 6.5 hours

Activity Fee: \$100 (ASHP member); \$150 (non-member)

Accreditation for Pharmacists



The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

These activities were presented as part of the 2021 Virtual Midyear Clinical Meeting. Learners who claimed ACPE credit for these activities as part of that meeting, should not claim ACPE credit again.

Target Audience

These recertification activities are intended for board certified pharmacists seeking to update their knowledge and skills in:

- Treatment and Prevention of HIV
- Fluid Resuscitation in Septic Shock
- 2020 Antimicrobial Resistant Gram-Negative Infection Treatment Guidelines
- Diuretic Resistance in AHF

Activity Overview

The Intensive Study Package is intended for board certified pharmacists in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS). Using a case-based approach, the activities provide high-level, interactive discussions on contemporary and emerging issues in pharmacotherapy.

The Pharmacotherapy Intensive Study Recertification Package consists of 4 activities (see table below) and provides up to 6.5 contact hours of continuing pharmacy education and/or recertification credit.

These activities are part of the ASHP professional development program for BCPS recertification approved by the BPS. For pharmacists who maintain more than one certification, three of the activities are approved for multiple specialties (see table below).

Recertification Credit*

Board certified pharmacists are eligible to receive up to 6.5 contact hours of recertification credit for completing this package. To earn recertification credit, learners must review the activity content and successfully complete the online assessments by the deadline. Only

Materials for this course will release 02/02/2022

completed assessments will be eligible for credit; no partial or incomplete assessments will be processed. You are allowed only one attempt to successfully complete this assessment.

Learning Activity	ACPE Number	Contact Hours	Specialty	Recertification Assessment
Long Acting Antiretroviral Therapy for the Treatment and Prevention of HIV Infection	0204-0000-21-315-H02-P	1.5 ACPE	BCPS	TBD%
Fluid Resuscitation Controversies in Adult and Pediatric Septic Shock – Does One Size Fit All?	0204-0000-21-246-H01-P	1.5 ACPE	BCPS, BCCCP, BCPPS	TBD%
Beyond the Top Line: A Point-Counterpoint Discussion of the 2020 Antimicrobial Resistant Gram-Negative Infection Treatment Guideline	0204-0000-21-269-H01-P	2 ACPE	BCPS, BCCCP	TBD%
Resistance is Futile: Overcoming Diuretic Resistance in Acute Heart Failure	0204-0000-21-305-H01-P	1.5 ACPE	BCPS, BCCCP	TBD%
Total Contact Hours		6.5 BPS		

Long Acting Antiretroviral Therapy for the Treatment and Prevention of HIV Infection

0204-0000-21-315-H02-P

Learning Objectives

At the conclusion of this application-based educational activity, participants should be able to do the following:

- Describe the pharmacology and pharmacokinetics of cabotegravir and rilpivirine as long-acting injectable antiretroviral therapy agents.
- Apply clinical trial data and the principles of antiretroviral therapy to determine appropriate candidates for long-acting cabotegravir and rilpivirine for HIV treatment.
- Apply clinical trial data and the principles of HIV pre-exposure prophylaxis to determine appropriate candidates for long-acting cabotegravir for HIV prevention.
- Recommend strategies for solving drug therapy related problems common to long-acting antiretroviral agents including missed doses, adverse drug reactions and drug-drug interactions.

This activity is approved for Board Certified Pharmacotherapy Specialist (BCPS) recertification credit.

Fluid Resuscitation Controversies in Adult and Pediatric Septic Shock – Does One Size Fit All?

0204-0000-21-246-H01-P

Learning Objectives

At the conclusion of this application-based educational activity, participants should be able to do the following:

- Analyze recommendations for the initial fluid bolus dose for adult patients with septic shock.
- Select an appropriate fluid bolus dose for a pediatric patient with septic shock.
- Recommend the most appropriate type of fluid for an adult or pediatric patient with septic shock.
- Evaluate strategies for assessing fluid responsiveness in adults.
- Recognize criteria for reassessment of fluid management in children.

This activity is approved for Board Certified Critical Care Pharmacist (BCCCP), Board Certified Pediatric Pharmacy Specialist (BCPPS), and Board Certified Pharmacotherapy Specialist (BCPS) recertification credit.

Beyond the Top Line: A Point-Counterpoint Discussion of the 2020 Antimicrobial Resistant Gram-Negative Infection Treatment Guideline

0204-0000-21-269-H01-P

Learning Objectives

At the conclusion of this application-based educational activity, participants should be able to do the following:

- Discuss broad-spectrum agents that are included in the 2020 gram-negative treatment guidelines.
- Recommend evidence-based therapies for antibiotic-resistant gram-negative infections.
- Assess clinical scenarios in which guideline non-preferred therapy may be considered.

This activity is approved for Board Certified Critical Care Pharmacist (BCCCP) and Board Certified Pharmacotherapy Specialist (BCPS) recertification credit

Materials for this course will release 02/02/2022

Resistance is Futile: Overcoming Diuretic Resistance in Acute Heart Failure

0204-0000-21-305-H01-P

Learning Objectives

At the conclusion of this application-based educational activity, participants should be able to do the following:

- Given a patient failing to meet diuresis goals, identify etiologies of diuretic resistance and evidence-based strategies for management.
- Given a patient presenting with acute decompensated heart failure (ADHF) and volume overload, recommend an individualized strategy for relieving congestive symptoms using evidence-based literature.
- Given a patient failing to meet diuresis goals, apply literature to design a modified strategy for relieving congestive symptoms.

This activity is approved for Board Certified Critical Care Pharmacist (BCCCP) and Board Certified Pharmacotherapy Specialist (BCPS) recertification credit

Faculty

Monique R. Bidell, Pharm.D., BCPS

Clinical Pharmacy Specialist – Infectious Diseases
Massachusetts General Hospital
Boston, Massachusetts

Jennifer Cocohoba, Pharm.D., AAHIVP, BCPS

Professor, Department of Clinical Pharmacy
University of California San Francisco School of Pharmacy
Pharmacist, UCSF Womens' HIV Program

Zachary L. Cox, Pharm.D., FHFSA

Associate Professor
Lipscomb University College of Pharmacy
Nashville, Tennessee

Stormi E. Gale, Pharm.D., BCCP

Clinical Pharmacist – Cardiology Subject Matter Expert
Novant Health Matthews Medical Center
Baltimore, Maryland

Ronak G. Gandhi, Pharm.D., BCPS

Attending Clinical Pharmacist- Infectious Diseases
Massachusetts General Hospital
Boston, Massachusetts

Pete Johnson, Pharm.D., BCPS, BCPPS, FPPA, FCCM, FASHP

Professor—University of Oklahoma College of Pharmacy
CICU Pediatric Clinical Specialist—Oklahoma Children's Hospital
at OU Health
Oklahoma City, Oklahoma

Thomas P. Lodise, Pharm.D., PhD

Professor, Pharmacy Practice
Albany College of Pharmacy and Health Sciences
Albany, New York

Jason Schafer, Pharm.D., M.P.H., AAHIVP, BCIDP, BCPS, FASHP

Vice Chair and Professor, Department of Pharmacy Practice
Jefferson College of Pharmacy
Philadelphia, Pennsylvania

Elizabeth Sherman, Pharm.D., AAHIVP

Associate Professor, Department of Pharmacy Practice
Nova Southeastern University College of Pharmacy
Clinical Pharmacy Specialist, Memorial Healthcare System
Fort Lauderdale, Florida

Heather Torbic, Pharm.D., BCPS, BCCCP

Medical ICU Clinical Specialist—Cleveland Clinic
Cleveland, Ohio

*Content Matter Experts

Reviewers

Christopher Betz, Pharm.D., BCPS, FASHP, FKSH*
Snehal Bhatt, Pharm.D., BCPS-AQ Cardiology, FASHP, AAC*
Angela Bingham, Pharm.D., BCPS, BCNSP, BCCCP
Holly L. Byrnes, Pharm.D., BCPS
Susan R. Dombrowski, M.S., R.Ph.

Mary M. Hess, Pharm.D., FASHP, FCCM, FCCP, BCCCP
Kristi Hofer, Pharm.D.
Douglas Slain, Pharm.D., B.S.Pharm., BCPS, AQ-ID*
Paul M. Szumita, Pharm.D., BCCCP, BCPS, FASHP, FCCM
Jennifer Thackray, Pharm.D., BCPPS, BCPS

Field Testers

TBD

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education's Standards for Commercial Support and the Accreditation Council for Pharmacy Education's Standards for Commercial Support, ASHP requires that all individuals involved in the development of activity content disclose their relevant financial relationships. A person has a relevant financial relationship if the individual of his or her

Materials for this course will release 02/02/2022

spouse/partner has a financial relationship (e.g. employee, consultant, research grant recipient, speakers bureau, or stockholder) in any amount occurring in the last 12 months with a commercial interest whose products or services may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on the content.

All faculty and planners for ASHP education activities are qualified and selected by ASHP and required to disclose any relevant financial relationships with commercial interests. ASHP identifies and resolves conflicts of interest prior to an individual's participation in development of content for an educational activity. Anyone who refuses to disclose relevant financial relationships must be disqualified from any involvement with a continuing pharmacy education activity.

- Jennifer Cocohoba: ViiV: grant/research support
- Elizabeth Sherman: Merck: grant/research support
- Jason Schafer: Merck: advisory committee/board member, grant/research support; ViiV: advisory board
- Thomas Lodise: Melinta Therapeutics: Advisory Board, Consultant, Speaker's Bureau; Merck: Consultant, Grant Recipient; Shionogi: Advisory Board, Consultant, Speaker's Bureau; Spero Therapeutics: Advisory Board, Consultant

All other planners, presenters, reviewers, and ASHP staff and others with an opportunity to control content report no financial relationships relevant to this activity.

Methods and CE Requirements

Activities consist of audio/video/PDF files, an attestation statement, and activity evaluation. Learners must review all content and complete the attestation statement and course evaluation to receive continuing pharmacy education credit for each activity.

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.

System Technical Requirements

Learning activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and navigating web sites.

View the [minimum technical and system requirements](#) for learning activities.

Development

These activities were developed by ASHP.